Compare Quantumscape Corp (QS) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Stryker Corporation — how do they compare? Quantumscape Corp trades at $5.65 (market cap $3.72B), while Stryker Corporation trades at $309.5 (market cap $120.60B). The key difference: Stryker Corporation is far larger — about 32.4× Quantumscape Corp's market cap, and Stryker Corporation pays a 1.12% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| QS | SYK | |
|---|---|---|
Market Cap | $3.72B | $120.60B |
Sector | Consumer Cyclical | Technology |
52-Week High | $18.44 | $403.53 |
52-Week Low | $5.86 | $282.58 |
Enterprise Value | $2.89B | $132.36B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $6.05, up 3.24% on the day, amid a bearish technical signal and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, while cash flow remains dependent on financing activities. Recent news highlights a joint research agreement with Honda, providing optimism around solid-state battery development, though earnings misses in recent quarters temper near-term expectations.
The outlook remains speculative with high execution risk as QS transitions from R&D to commercialization. Investor sentiment is cautious, reflected in analyst holds and sells, but partnerships like Honda offer long-term potential. Key risks include sustained losses, EV market demand volatility, and manufacturing scalability challenges against established competitors.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
